|
2023 Guidance Reconciliation of Non-GAAP to GAAP Measures (Unaudited) |
||
|
FY23 Recurring revenue growth (a) |
||
|
Impact of foreign currency exchange |
— |
|
|
Recurring revenue growth constant currency – Non-GAAP |
6 – 9% |
|
|
FY23 Adjusted Operating income margin (b) |
||
|
Operating income margin % – GAAP |
Increase of ~ 150 bps |
|
|
Adjusted Operating income margin % – Non-GAAP |
Increase of ~ 50 bps |
|
|
FY23 Adjusted earnings per share growth rate (c) |
||
|
Diluted earnings per share – GAAP |
~13 – 17% growth |
|
|
Adjusted earnings per share – Non-GAAP |
7 – 11% growth |
|
Vir Biotechnology Gets Price Targets Cuts By Analysts After Q4 Results
Vir Biotechnology, Inc. (NASDAQ: VIR) reported worse-than-expected Q4 results.
Vir Biotechnology posted a Q4 loss of $0.76 per share, versus market expectations of $0.39 per share. The company’s quarterly sales came in at $49.41 million, versus estimates of $97.30 million.
